ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1683

Moving the ACR’s Reproductive Health Guidelines into Practice: Assessment of a Novel Reproductive Rheumatology ECHO

Megan Clowse1, Teresa Swezey2, Jerome (Jeff) Federspiel2, Catherine Sims2, Amanda Snyderman2, Amy Corneli2, Sarahn Wheeler2 and JoAnn Zell3, 1Duke University, Chapel Hill, NC, 2Duke University School of Medicine, Durham, NC, 3University of Colorado Anschutz Medical Campus, Denver, CO

Meeting: ACR Convergence 2023

Keywords: education, medical, pregnancy, Women's health

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: Abstracts: Reproductive Issues in Rheumatic Disorders

Session Type: Abstract Session

Session Time: 4:00PM-5:30PM

Background/Purpose: Project ECHO™ in an education model that links experts with community providers through a series of video teleconferences. Each conference involves a brief didactic session followed by a discussion of real patient cases. We piloted the first ECHO in reproductive rheumatology to increase rheumatologists’ knowledge and self-efficacy in providing reproductive health care.

Methods: The Project ECHO guides informed ReproRheum ECHO curriculum development, provider recruitment, logistics, and assessment. All ACR RISE Registry providers received email invitations. The ECHO was evaluated using interviews and pre/post surveys to assess provider knowledge, self-efficacy, and to identify program strengths, weaknesses, and solicit suggestions. Self-efficacy was assessed using a modified validated Self-Efficacy 12 survey.

Results: A total of 12 providers, 8 rheumatology providers (4 MD, 2 NP, 2 fellows) and 4 experts (2 reproductive rheumatologists, 2 MFM), participated in the ReproRheum ECHO’s 6, 1-hour sessions from January-March 2023. Feasibility was demonstrated: all but one provider attended all sessions.

Knowledge of the rate of birth defects after exposure to azathioprine and mycophenolate both significantly increased. Provider self-efficacy increased significantly (6.8 +/- 1.2 pre-ECHO to 8.1 +/- 0.5 post-ECHO, p=0.03). All participants ‘agreed’ or ‘strongly agreed’ that they had increased confidence in their ability to answer colleagues’ questions and guide patients’ choices in contraception and medication in pregnancy.

In interviews, providers described the didactic and case discussion sections as being the most valuable, noting the combination allowed them to apply the knowledge in clinical care. They expressed appreciating the diversity of perspectives and experiences of rheumatologists from across the US and the inclusion of MFM experts. Providers said they were satisfied with the amount of facts and experienced very few barriers to attendance. Providers shared they had increased knowledge, comfort and confidence in speaking with patients about reproductive health. Providers who were not recording reproductive health information routinely before the ECHO said that they had added pregnancy counseling sections to their notes. Nearly all providers viewed the LupusPregnancy.org and ReproRheum.Duke.edu handouts as useful during patient discussions. Some providers said they shared handouts with patients, while others had verbally reviewed them together. Nearly all providers said they would definitely attend future ECHO sessions and that they would definitely recommend the ECHO to other rheumatologists and midlevel providers.

Suggestions for improvement included having patients share their perspective, role-playing patient counseling, and enhancing curricula with articles and summary sheets.

Conclusion: The pilot ReproRheum ECHO was feasible and improved knowledge and self-efficacy among rheumatologists in reproductive health. We hope to expand to multiple audiences using tailored content, including fellows, rural providers and advanced practice providers. This model is a promising approach to improving reproductive health care for women with rheumatic disease.


Disclosures: M. Clowse: Exagen, 5, GlaxoSmithKlein(GSK), 2, 5, Immunovant, 5, UCB, 2, 5; T. Swezey: None; J. Federspiel: Hemosquid, 2; C. Sims: UCB, 5; A. Snyderman: GSK, 5, UCB, 5; A. Corneli: None; S. Wheeler: None; J. Zell: None.

To cite this abstract in AMA style:

Clowse M, Swezey T, Federspiel J, Sims C, Snyderman A, Corneli A, Wheeler S, Zell J. Moving the ACR’s Reproductive Health Guidelines into Practice: Assessment of a Novel Reproductive Rheumatology ECHO [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/moving-the-acrs-reproductive-health-guidelines-into-practice-assessment-of-a-novel-reproductive-rheumatology-echo/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/moving-the-acrs-reproductive-health-guidelines-into-practice-assessment-of-a-novel-reproductive-rheumatology-echo/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology